Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016
Published Jun 28, 2016
107 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016, provides in depth analysis on Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted pipeline therapeutics.

The report provides comprehensive information on the Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49)
- The report reviews Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
- The report assesses Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects

  
Source:
Document ID
GMDHC0051TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Overview91
Therapeutics Development104
  Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Stage of Development101
  Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Therapy Area111
  Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Indication122
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Pipeline Products Glance143
  Late Stage Products141
  Early Stage Products151
  Unknown Stage Products161
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Companies174
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Products under Development by Universities/Institutes212
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Therapeutics Assessment237
  Assessment by Monotherapy/Combination Products231
  Assessment by Mechanism of Action242
  Assessment by Route of Administration262
  Assessment by Molecule Type282
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Companies Involved in Therapeutics Development3012
  Adamis Pharmaceuticals Corporation301
  Argos Therapeutics, Inc.311
  Asterias Biotherapeutics, Inc.321
  e-Therapeutics Plc331
  F. Hoffmann-La Roche Ltd.341
  Inovio Pharmaceuticals, Inc.351
  Invectys SA361
  Johnson &Johnson371
  Komipharm International Co., Ltd.381
  Mediolanum farmaceutici S.p.A.391
  Ultimovacs AS401
  Vaxon Biotech411
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Drug Profiles4242
  ASTVAC-1 Drug Profile422
  ASTVAC-2 Drug Profile442
  ETS-2300 Drug Profile461
  Gene Therapy to Activate Telomerase for Alzheimer's Disease Drug Profile471
  Gene Therapy to Activate Telomerase for Alzheimer s Disease and Atherosclerosis Drug Profile481
  Gene Therapy to Activate Telomerase for Aplastic Anemia Drug Profile491
  GX-301 Drug Profile501
  imetelstat sodium Drug Profile517
  INO-1400 Drug Profile581
  INO-5400 Drug Profile591
  INVAC-1 Drug Profile601
  KML-001 Drug Profile612
  rocapuldencel-T Drug Profile637
  Small Molecule to Target Telomerase for Lung Cancer Drug Profile701
  Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia Drug Profile711
  TeloB-VAX Drug Profile721
  tertomotide Drug Profile732
  UCPVax Drug Profile751
  UV-1 Drug Profile761
  Vaccine to Target Telomerase for Oncology Drug Profile771
  Vaccine to Target Telomerase for Solid Tumor Drug Profile781
  Vbx-016 Drug Profile791
  Vbx-026 Drug Profile801
  Vx-001 Drug Profile812
  Vx-006 Drug Profile831
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Dormant Projects844
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Discontinued Products884
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Featured News &Press Releases9214
  Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review921
  May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting921
  Apr 20, 2016: Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting932
  Mar 23, 2016: Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy951
  Mar 02, 2016: New trial launched to test cancer vaccine952
  Feb 24, 2016: Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1971
  Jan 21, 2016: Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial981
  Jan 14, 2016: Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes991
  Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis1001
  Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting1001
  Nov 05, 2015: Janssen to Present Posters on Imetelstat at the 2015 American Society of Hematology Annual Meeting1011
  Oct 30, 2015: Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine1021
  Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis1031
  Sep 02, 2015: Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancies1031
  Aug 10, 2015: Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma1042
Appendix1062
  Methodology1061
  Coverage1061
  Secondary Research1061
  Primary Research1061
  Expert Panel Validation1061
  Contact Us1061
  Disclaimer1071

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Telomerase-Reverse-Transcriptase-Telomerase-or-HEST2-or-Telomerase-Catalytic-Subunit-or-Telomerase-Associated-Protein-2-or-EC-2-7-7-49-Pipeline-Review-H1-2016-2088-16021>
  
APA:
Global Markets Direct - Market Research. (2016). Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Telomerase-Reverse-Transcriptase-Telomerase-or-HEST2-or-Telomerase-Catalytic-Subunit-or-Telomerase-Associated-Protein-2-or-EC-2-7-7-49-Pipeline-Review-H1-2016-2088-16021>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.